Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$271.71 USD

271.71
847,461

-0.89 (-0.33%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $271.82 +0.11 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sriparna Ghosal headshot

3 Large-Cap MedTech Stocks to Buy on Northbound Market Trend

by Sriparna Ghosal

Backed by an upward trend of share prices and projections of robust earnings growth rates, there are a few MedTech stocks which are ideal for long-term bet.

Zacks Equity Research

Zacks.com featured highlights include: Dollar General, SYNNEX, ResMed, Skyworks and Werner Enterprises

by Zacks Equity Research

Zacks.com featured highlights include: Dollar General, SYNNEX, ResMed, Skyworks and Werner Enterprises

Zacks Equity Research

Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid

by Zacks Equity Research

Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.

Zacks Equity Research

3 Inexpensive MedTech Gainers of 2H20 Beyond TMO and RMD

by Zacks Equity Research

Here we look at three cheap MedTech stocks that investors can take a look at apart from giants like Thermo Fisher and ResMed that are expensive.

Zacks Equity Research

ResMed (RMD) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sweta Killa headshot

5 Great Dividend Growth Stocks for Second Half

by Sweta Killa

In the low-rate environment and amid stock market uncertainty, investors are in search of consistent income.

Debanjana Dey headshot

4 Best MedTech Stocks to Combat Coronavirus Crisis on Strong ROE

by Debanjana Dey

Here are some MedTech stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

    Zacks Equity Research

    Walgreens Boots (WBA) Q3 Earnings Lag Estimates, Margin Down

    by Zacks Equity Research

    Walgreens Boots' (WBA) fiscal third-quarter results reflect overall top line improvement despite COVID-19-led business disruptions.

    Trina Mukherjee headshot

    Medical Products Industry's Near-Term Outlook Lacks Spark

    by Trina Mukherjee

    AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.

    Zacks Equity Research

    Here is Why Growth Investors Should Buy ResMed (RMD) Now

    by Zacks Equity Research

    ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.

    Sreoshi Bera headshot

    Sustainable Investment Forms Part of the New Normal: 5 Picks

    by Sreoshi Bera

    ESG policies and practices yielded positive outcomes during the coronavirus slump. Also, millennials-driven sustainable investing trend will continue post-pandemic.

    Trina Mukherjee headshot

    Remote Patient Monitoring Gains Prominence: 3 Stocks to Watch

    by Trina Mukherjee

    Let's keep a watch on three stocks that are committed toward enhancing and offering RPM to fight against coronavirus.

    Zacks Equity Research

    Here's Why You Should Hold on to ResMed (RMD) Stock for Now

    by Zacks Equity Research

    Investors continue to be upbeat about ResMed (RMD) owing to its strong emphasis on product development and consistent high demand for its critical care products.

    Trina Mukherjee headshot

    3 MedTech Stocks to Watch Amid Coronavirus Catastrophe

    by Trina Mukherjee

    Let's keep a watch on three stocks that have displayed strong performance amid market turmoil led by the ongoing pandemic.

    Debanjana Dey headshot

    Ventilator Industry Pumps Up Amid Coronavirus: 3 Stocks in Focus

    by Debanjana Dey

    Amid the pandemic crisis, the ventilator industry gains on contributions from companies across various sectors.

    Zacks Equity Research

    ResMed (RMD) Up 3.5% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Equity Research

    ResMed (RMD) Launches Digital Tool for Remote Mask Selection

    by Zacks Equity Research

    Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.

      Zacks Equity Research

      Here's Why You Should Hold on to ResMed (RMD) Stock for Now

      by Zacks Equity Research

      Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.

        Zacks Equity Research

        ResMed Grows on Solid Ventilator Sales Amid Coronavirus Woes

        by Zacks Equity Research

        ResMed (RMD) global sales increase on ramped-up demand for its critical care support products.

        Zacks Equity Research

        ResMed (RMD) Q3 Earnings Top on Higher Ventilator Sales

        by Zacks Equity Research

        ResMed's (RMD) adjusted gross margin improves on benefits from changes in product mix, and manufacturing and procurement efficiencies.

        Zacks Equity Research

        IDEXX (IDXX) Q1 Earnings Top Estimates, Margins Decline

        by Zacks Equity Research

        IDEXX Laboratories (IDXX) companion animal clinical visits decrease due to the impact of the coronavirus pandemic.

        Zacks Equity Research

        Align Technology (ALGN) Q1 Earnings Miss, Margins Down

        by Zacks Equity Research

        Align Technology's (ALGN) Scanner and Services reports COVID-19-led lower sales in North America and APAC region.

        Urmimala Biswas headshot

        LabCorp's (LH) Q1 Earnings Beat Estimates, Margins Down

        by Urmimala Biswas

        LabCorp's (LH) Covance Drug Development revenues improve despite COVID-19 hurdles.

        Zacks Equity Research

        Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline

        by Zacks Equity Research

        The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.

        Zacks Equity Research

        Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve

        by Zacks Equity Research

        Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.